Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Sep;32(9):2140-2142.
doi: 10.1681/ASN.2021020188. Epub 2021 Aug 2.

Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection

Gemma D Banham  1   2 , Alexandra Godlee  2   3 , Sian E Faustini  4 , Adam F Cunningham  4 , Alex Richter  2   4 , Lorraine Harper  2   5 ; COVID-HD Birmingham Study Group
Affiliations
Observational Study

Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection

Gemma D Banham et al. J Am Soc Nephrol. 2021 Sep.

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.

Keywords: COVID-19; SARS-CoV-2; antibody; hemodialysis.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
The serological response to SARS-CoV-2 and the risk of reinfection. Gray and red lines represent individual antibody ratios over time for patients who were antibody positive during the first wave and alive at the start of the second wave. Patients testing PCR+ during the second wave are shown by red lines. Patients who did not test PCR+ during the second wave are shown by gray lines. The predicted mean IgGAM serological response for the cohort is shown by solid black lines. The threshold for antibody positivity is represented by a dotted line.
See this image and copyright information in PMC

References

    1. The Renal Association B : UK Renal Registry (2020) COVID-19 surveillance report for renal centres in the UK: A summary of the first wave of the pandemic – March to August 2020. Available at: https://renal.org/sites/renal.org/files/covid_report_first_wave_FINAL_04.... Accessed January 4, 2021
    1. Savino M, Casula A, Santhakumaran S, Pitcher D, Wong E, Magadi W, et al. .: Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: A UK Renal Registry data analysis. PLoS One 15: e0241263, 2020 - PMC - PubMed
    1. Cook AM, Faustini SE, Williams LJ, Cunningham AF, Drayson MT, Shields AM, et al. .: Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients. J Immunol Methods 494: 113046, 2021 - PMC - PubMed
    1. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. .: Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370: 1227–1230, 2020 - PMC - PubMed
    1. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. .: Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371: eabf4063, 2021 - PMC - PubMed

Publication types

MeSH terms

Substances